

forth as SEQ ID NO:5. Support for the amendment to the specification can be found for example, in the specification at page 12, lines 31-34.

Applicant has also amended the specification to include substitute pages 75-101. Substitute pages 75-101 contain a Sequence Listing for the above-referenced application which Applicant respectfully submits complies with the requirements of 37 CFR 1.821-1.825. In particular, Applicant has corrected minor errors in the Sequence Listing as indicated on the Raw Sequence Listing Error Report attached to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed from the Patent Office with the instant office action (September 28, 1999).

Applicant has further submitted on even date herewith a computer-readable form (diskette) of this sequence which is identical in substance to the Sequence Listing on substitute pages 75-101 submitted herewith.

No new matter has been added. Applicant respectfully requests that the amendment to the specification be entered.

Election/Restriction

The Examiner has required restriction to one of the following inventions under 35 U.S.C. 121:

- I. Claims 1-17, drawn to nucleic acids, vectors, host cells and methods of producing CRSP protein, classifiable in class 536, subclass 23.1 and class 435, subclasses 325 and 69.1.
- II. Claims 18 and 19, drawn to a transgenic animal comprising a transgene encoding CRSP, classifiable in class 800, subclass 8.
- III. Claims 20-31, drawn to isolated CRSP proteins and fusion proteins, classifiable in class 530, subclass 350.

- IV. Claims 32-34, drawn to antibodies which specifically bind CRSP, classifiable in class 424, subclass 130.
- V. Claim 38, drawn to a method of modulating a cell-associated activity by stimulating CRSP protein activity or expression classifiable in class 435, subclass 4.
- VI. Claim 40, drawn to a method of modulating a cell-associated activity by inhibiting CRSP protein activity or expression, using anti-sense, classifiable in class 536, subclass 24.5.
- VII. Claim 41, drawn to a method of modulating a cell-associated activity by inhibiting CRSP protein activity or expression, using an antibody, classifiable in class 424, subclass 130.
- VIII. Claim 44, drawn to a method of treating a subject with a small molecule, classifiable in class 514, subclass 1.
- IX. Claim 45, drawn to a method of treating a subject with a protein, classifiable in class 514, subclass 2.
- X. Claim 46, drawn to a method of treating a subject with a nucleic acid, classifiable in class 514, subclass 44.
- XI. Claims 50, 51 and 55, drawn to method of detecting for the presence of CRSP activity using nucleic acid, classifiable in class 435, subclass 6.
- XII. Claims 52, 53 and 56, drawn to method of detecting for the presence of CRSP activity using antibodies, classifiable in class 435, subclass 7.1.
- XIII. Claim 59, drawn to an assay for detecting a genetic alteration in a cell, classifiable in class 435, subclass 6.
- XIV. Claim 60, drawn to an assay for detecting a genetic alteration in a cell, classifiable in class 435, subclass 91.
- XV. Claims 37 and 42 are generic to groups V, VI and VII. Claim 39 is generic to groups VI and VII. Claims 43, 47 and 48 are generic to groups VIII, IX and X. Claims 49, 54, and 57 are generic to groups XI and XII. Claim 58 is generic to groups XIII and XIV. Election of any one of the groups listed immediately above will result in examination of the corresponding generic claim(s).

Applicant hereby elects Group III (claims 20-31) for prosecution in the present application without traverse. Non-elected claims 1-20 and 32-60 as well as elected

claims 20-31 have been canceled from the application. New claims 61-87 have been added. Accordingly, claims 61-87 are currently pending.

Support for the new claims can be found throughout the specification and claims as-filed. In particular, support for new claims 61-62, 69-70 and 85 can be found in the specification at least, for example, at page 4, lines 29-31, at page 20, lines 2-12, and at page 26, lines 31-32, as well as in claim 29, as originally filed. Support for new claims 63-68 and 81-84 can be found in the specification at least, for example, at page 7, line 31 through page 8, line 37, at page 10, lines 8-10, and at page 12, lines 29-35, as well as in claims 27-28 as originally-filed. Support for new claims 71-72 can be found in the specification at least, for example, at page 2, lines 27-32 and at page 15, lines 4-11, as well as in claims 23-24 as originally filed. Support for new claims 73-74 can be found in the specification at least, for example, at page 19, line 8-15. Support for new claims 75-76 can be found at least, for example, in claim 21 as originally filed, as well as in the specification at page 4, line 32 through page 5, line 8, and at page 16, lines 3-11. Support for new claims 77-80 can be found in the specification at least, for example, at page 26, lines 23-25. Support for new claim 86 can be found in the specification at least, for example, at page 28, lines 11-36, as well as in claims 30-31, as originally filed. Support for new claim 87 can be found in the specification at least, for example, at page 42, line 33 through page 43, line 7, as well as in claim 35 as originally filed.

No new matter has been added.


SUMMARY

Any cancellation of the claims was done solely to expedite the prosecution of the application. Applicant reserves the right to pursue the claims as originally filed in this or a separate application(s). As the above amendment does not affect the issue of patentability, it is respectfully requested that it be entered.

If a telephone conversation with Applicant's Attorney would expedite the prosecution of the above-identified application, the examiner is urged to call Applicant's Attorney at (617) 227-7400.

Date: **December 14, 1999**

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By 
DeAnn F. Smith
Reg. No. 36,683
28 State Street
Boston, MA 02109
(617) 227-7400
(617) 742-4214